Agents Targeting Prostate Cancer Bone Metastasis

Author(s): Khalid S. Mohammad, Pierrick G. Fournier, Theresa A. Guise, John M. Chirgwin.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 9 , Issue 10 , 2009

Become EABM
Become Reviewer


Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bonetargeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.

Keywords: Prostate cancer, bone, metastasis, osteolytic, osteoblastic, bisphosphonate, RANK ligand, endothelin, TGF-beta

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [1079 - 1088]
Pages: 10
DOI: 10.2174/187152009789735008
Price: $58

Article Metrics

PDF: 7